製品の概要

  • 製品名Anti-KRIT1 antibody
    KRIT1 一次抗体 製品一覧
  • 製品の詳細
    Rabbit polyclonal to KRIT1
  • アプリケーション適用あり: WB, ICC/IFmore details
  • 種交差性
    交差種: Human
  • 免疫原

    Highly pure (>95%) recombinant Human KRIT1 (amino acids 1-736; UniProt ID O00522) derived from E. coli and fused to a C terminal His tag.

  • ポジティブ・コントロール
    • Human foreskin tissue

製品の特性

アプリケーション

Our Abpromise guarantee covers the use of ab111504 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

アプリケーション Abreviews 特記事項
WB Use a concentration of 2 - 5 µg/ml. Predicted molecular weight: 84 kDa.
ICC/IF Use a concentration of 2 - 10 µg/ml.

ターゲット情報

  • 機能Negative regulator of angiogenesis. Inhibits endothelial proliferation, apoptosis, migration, lumen formation and sprouting angiogenesis in primary endothelial cells. Promotes AKT phosphorylation in a NOTCH-dependent and independent manner, and inhibits EKR1/2 phosphorylation indirectly through activation of the DELTA-NOTCH cascade. Acts in concert with CDH5 to establish and maintain correct endothelial cell polarity and vascular lumen and these effects are mediated by recruitment and activation of the Par polarity complex and RAP1B. Required for the localization of phosphorylated PRKCZ, PARD3, TIAM1 and RAP1B to the cell junction. Plays an important role in the maintenance of the intracellular reactive oxygen species (ROS) homeostasis to prevent oxidative cellular damage. Regulates the homeostasis of intracellular ROS through an antioxidant pathway involving FOXO1 and SOD2. Facilitates the down-regulation of cyclin D1 levels required for cell transition from proliferative growth to quiescence by preventing the accumulation of intracellular ROS through the modulation of FOXO1 and SOD2 levels.
  • 組織特異性Low levels in brain. Very weak expression found in heart and muscle.
  • 関連疾患Defects in KRIT1 are the cause of cerebral cavernous malformations type 1 (CCM1) [MIM:116860]. Cerebral cavernous malformations (CCMs) are congenital vascular anomalies of the central nervous system that can result in hemorrhagic stroke, seizures, recurrent headaches, and focal neurologic deficits. CCMs have an incidence of 0.1%-0.5% in the general population and usually present clinically during the 3rd to 5th decade of life. The lesions are characterized by grossly enlarged blood vessels consisting of a single layer of endothelium and without any intervening neural tissue, ranging in diameter from a few millimeters to several centimeters.
  • 配列類似性Contains 4 ANK repeats.
    Contains 1 FERM domain.
  • 細胞内局在Membrane. Cell junction. KRIT1 and CDH5 reciprocally regulate their localization to endothelial cell-cell junctions.
  • Information by UniProt
  • 参照データベース
  • 別名
    • Ankyrin repeat containing protein Krit1 antibody
    • CAM antibody
    • CCM 1 antibody
    • CCM1 antibody
    • Cerebral cavernous malformations 1 antibody
    • Cerebral cavernous malformations 1 protein antibody
    • Krev interaction trapped 1 antibody
    • Krev interaction trapped protein 1 antibody
    • KRIT 1 antibody
    • KRIT1 ankyrin repeat containing antibody
    • KRIT1 antibody
    • KRIT1_HUMAN antibody
    see all

Anti-KRIT1 antibody 画像

  • Immunofluorescent staining of Human foreskin, using ab111504 at a 1/50 dilution (red). Costaining of endothelial cells is with anti CD31 (green). Note specific staining in the wall of a subset of vessel. Nuclei are counter-stained with Dapi (blue).

Anti-KRIT1 antibody (ab111504) 使用論文

ab111504 has not yet been referenced specifically in any publications.

Product Wall

There are currently no Abreviews or Questions for ab111504.
Please use the links above to contact us or submit feedback about this product.

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"